Dr. Steven Jeffery reviews studies describing the clinical use of small intestinal submucosa (SIS) in hard-to-heal and complex acute wounds.1
Dr. Jeffery also briefly describes two clinical cases using SIS.
Dr. Jeffery describes the clinical evidence for using a cellular, acellular, and matrix-like product (CAMP), SIS, to treat hard-to-heal wounds, such as diabetic foot ulcers, venous leg ulcers, pressure ulcers, and arterial leg ulcers.
There are over 30 clinical studies looking at using SIS for hard-to-heal and complex acute indications; 13 are comparative studies. Dr. Jeffery discusses the evidence for the efficacy of SIS in treating the four types of hard-to-heal wounds listed above, as well as for complex acute wounds. Next, he presents the evidence of the cost effectiveness of using SIS to treat diabetic foot ulcers and venous leg ulcers. Dr. Jeffery reviews studies that found that while adding SIS to a standard-of-care treatment added product cost, using SIS translated into lower overall treatment costs. This is because much of the cost of wound management is related to healthcare resources like nursing visits, and these were lower when using SIS. He also gives examples of complex acute wounds treated with SIS. Lastly, he discusses the evidence of the benefits of treatment with SIS, such as faster time to healing, fewer dressing changes, reduced wound pain, and reduced inflammation.
1 Jeffery S. Clinical benefits of small intestinal submucosa extracellular matrix and review of the evidence. J Wound Care. 2023;32(1 Suppl 2):S11-S19.